免疫肿瘤学超越 TIL：释放 TILC。
Immuno-Oncology beyond TILs: Unleashing TILCs.
机构信息
Innate Pharma Research Laboratories, Innate Pharma, Marseille, France.
Innate Pharma Research Laboratories, Innate Pharma, Marseille, France; Aix Marseille University, CNRS, INSERM, CIML, Marseille, France; APHM, Hôpital de la Timone, Service d'Immunologie, Marseille-Immunopôle, Marseille, France.
出版信息
Cancer Cell. 2020 Apr 13;37(4):428-430. doi: 10.1016/j.ccell.2020.03.021.
Innate lymphoid cells (ILCs) are detected in multiple tumor types, but their contribution to tumor immunity remains unclear. Moral et al. show that a subset of tumor ILCs (TILCs) may participate in an organ-specific immune response and can be unleashed by PD-1 blockers to sustain tumor-specific T cell responses.
先天淋巴细胞（ILCs）在多种肿瘤类型中被检测到，但它们对肿瘤免疫的贡献尚不清楚。Moral 等人表明，肿瘤 ILCs（TILCs）的一个亚群可能参与器官特异性免疫反应，并可被 PD-1 阻断剂激活以维持肿瘤特异性 T 细胞反应。
Zotero 插件